Loading clinical trials...
Loading clinical trials...
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Zymeworks BC Inc.
NCT06902246 · Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
NCT07422753 · Hepatocellular Carcinoma (HCC)
NCT07175441 · Advanced Unresectable Hepatocellular Carcinoma
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT07218913 · Hearing Loss, Metastatic Malignant Germ Cell Tumor, and more
UCSF Comprehensive Cancer Center
San Francisco, California
University of California Los Angeles - Cancer Care - Santa Monica (UCLA)
Santa Monica, California
Norton Cancer Institute
Louisville, Kentucky
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions